Spinal relapse of Erdheim–Chester disease detected on 18F-FDG PET/CT Authors: Yassir Benameur, Omar Ait Sahel, Jaafar El Bakkali, Salah Nabih Oueriagli, Ikram Zahfir, Meryem Aboussabr, Abderrahim Doudouh Published: 2026 Erdheim–Chester disease (ECD) is a rare clonal non-Langerhans cell histiocytosis, characterized histologically by foamy histiocytes that are CD68-positive and CD1a-negative, and radiologically by symmetric osteosclerotic lesions of the long bones [1]. The disease can involve multiple organ systems, including the skeleton, central nervous system (CNS), cardiovascular system, lungs, and retroperitoneum. CNS involvement occurs in up to 50% of cases and is associated with a poor prognosis. Although spinal involvement is uncommon, it is typically symptomatic when present [1]. Here, we describe a case of ECD initially presenting with hypothalamic-pituitary axis involvement, followed by an asymptomatic spinal relapse detected on fuorine-18 fluorodeoxyglucose positron emission tomography/computed tomography (18F-FDG PET/CT), underscoring the importance of long-term, multimodal imaging surveillance. A 26-year-old woman presented with polyuria–polydipsia and diffuse bone pain, particularly in the femorotibial regions. Central diabetes insipidus was diagnosed, and brain magnetic resonance imaging (MRI) revealed thickening of the pituitary stalk. Bone scintigraphy showed increased radiotracer uptake in the humeri, femurs, and right maxillary sinus. A tibial biopsy confirmed ECD, with histological findings positive for CD68 and negative for CD1a. The patient was started on interferon-alpha and vasopressin therapy, resulting in both clinical and radiological stabilization. This stable phase lasted four years, after which the patient developed new symptoms, including cervical spine and rib pain, as well as refractory headaches. Repeat bone scintigraphy and MRI revealed new skeletal lesions involving the interorbital region, mandible, cervical and thoracic spine, ribs, and tibia. Cerebral MRI additionally demonstrated a parasellar lesion. 18F-FDG PET/CT confirmed hypermetabolism in the parasellar region and incidentally identified hypermetabolic intramedullary lesions at T5–T6 and T12–L2 (Fig. 1). Spinal MRI corroborated the presence of epidural thickening at these levels. Despite these imaging findings, neurological examination and electromyography (EMG) were normal, and the patient remained asymptomatic regarding spinal involvement. Given the CNS and epidural disease progression, molecular testing was performed. Detection of the BRAF V600E mutation prompted the initiation of targeted therapy with vemurafenib under hematology supervision. The patient remains under close clinical and imaging follow-up. Erdheim–Chester disease is a rare non-Langerhans cell histiocytosis characterized by a heterogeneous spectrum of clinical manifestations. While involvement of the long bones and CNS is relatively common, spinal (medullary) involvement is exceedingly rare and has been only sparsely reported in the literature [2]. Most documented cases of spinal involvement are clinically apparent and symptomatic [3], typically presenting with back pain, radiculopathy, or myelopathy secondary to spinal cord compression [3]. In contrast, the present case is unusual in that the spinal lesions were entirely asymptomatic, highlighting a diagnostic challenge and underscoring the importance of sensitive imaging modalities for effective disease surveillance. In this context, 18F-FDG PET/CT proved instrumental in identifying the medullary lesions. This hybrid imaging technique provides a metabolic perspective, enabling the detection of active disease even in the absence of overt anatomical abnormalities. In our patient, PET/CT revealed hypermetabolic epidural lesions at the T5–T6 and T12–L2 levels, despite the absence of neurological signs or symptoms. These findings were subsequently confirmed by spinal MRI. Without PET/CT, these silent lesions may have gone undetected, potentially delaying appropriate therapeutic intervention. The utility of PET/CT in identifying occult or subclinical disease in ECD is well documented. A pivotal aspect of this case was the identification of the BRAF V600E mutation, a genetic alteration found in approximately 50–60% of ECD patients [4]. This discovery carried both diagnostic and therapeutic implications. From a therapeutic perspective, it prompted the initiation of vemurafenib, a selective BRAF inhibitor that has shown efficacy in BRAF-mutated ECD, including cases with CNS involvement or refractory disease. Following treatment, the patient experienced both clinical and radiological stabilization, consistent with published data supporting the effectiveness of targeted therapy in this setting [5]. This case illustrates the exceptional nature of spinal medullary involvement in ECD and underscores the critical role of 18F-FDG PET/CT in detecting clinically silent but metabolically active lesions. The identification of a BRAF V600E mutation enabled the initiation of targeted therapy with vemurafenib, highlighting the increasing relevance of precision medicine in the management of ECD. The integration of functional imaging and molecular profiling is essential for accurate disease monitoring and personalized treatment in this rare and complex condition.